{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Weber JS"],"funding":["NCI NIH HHS"],"pagination":["324-333"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9444873"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["32(5)"],"pubmed_abstract":["Checkpoint immunotherapies (CPIs) have improved outcomes for metastatic melanoma patients, with objective response rates to combination ipilimumab and nivolumab of ~58%. Preclinical data suggest that histone deacetylase (HDAC) inhibition enhances antitumor immune activity and may augment CPI. In a phase Ib open-label pilot trial (NCT03565406), patients with therapy-naive metastatic melanoma were treated with the class I/IV HDAC inhibitor mocetinostat orally three times a week in combination with nivolumab and ipilimumab every 3 weeks for 12 weeks followed by 12-week maintenance cycles of nivolumab every 2 weeks and mocetinostat at the same dose and schedule as induction. The endpoints of the trial were safety, definition of a recommended phase 2 dose, preliminary assessment of response, an"],"journal":["Melanoma research"],"pubmed_title":["Clinical and immune correlate results from a phase 1b study of the histone deacetylase inhibitor mocetinostat with ipilimumab and nivolumab in unresectable stage III/IV melanoma."],"pmcid":["PMC9444873"],"funding_grant_id":["R00 CA230201","K99 CA230201"],"pubmed_authors":["Levinson BA","Weber JS","Pavlick AC","Woods DM","Laino AS"],"additional_accession":[]},"is_claimable":false,"name":"Clinical and immune correlate results from a phase 1b study of the histone deacetylase inhibitor mocetinostat with ipilimumab and nivolumab in unresectable stage III/IV melanoma.","description":"Checkpoint immunotherapies (CPIs) have improved outcomes for metastatic melanoma patients, with objective response rates to combination ipilimumab and nivolumab of ~58%. Preclinical data suggest that histone deacetylase (HDAC) inhibition enhances antitumor immune activity and may augment CPI. In a phase Ib open-label pilot trial (NCT03565406), patients with therapy-naive metastatic melanoma were treated with the class I/IV HDAC inhibitor mocetinostat orally three times a week in combination with nivolumab and ipilimumab every 3 weeks for 12 weeks followed by 12-week maintenance cycles of nivolumab every 2 weeks and mocetinostat at the same dose and schedule as induction. The endpoints of the trial were safety, definition of a recommended phase 2 dose, preliminary assessment of response, an","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Oct","modification":"2026-05-29T08:04:47.373Z","creation":"2025-04-05T15:24:11.493Z"},"accession":"S-EPMC9444873","cross_references":{"pubmed":["35678233"],"doi":["10.1097/CMR.0000000000000818","10.1097/cmr.0000000000000818"]}}